**[414] NIBS NEUROSCIENCE TECHNOLOGIES: PRE-PATHOLOGICAL DIAGNOSIS.**

**Iftach Dolev1, 1 Nibs Neuroscience Technologies**

* **Investment Rational**

NIBS Neuroscience Technologies develops a breakthrough brain imaging technology, creating a 3D high temporal resolution image, reflecting brain network state, the key measurement for the identification of various brain disorders, from Alzheimer's disease, through focal epilepsy to chronic pain. Existing neuroimaging advanced technologies as MRI, CT and EEG lack the ability to successfully cope with brain disorders. The main problem remains late and non-specific diagnosis. Led by Neuroscientists Dr. Dolev and Dr. Fogel, NIBS system revolutionizes brain imaging, creating a new measuring tool and scale to diagnose early stage, pre-pathological changes in brain function.

* **Business Strategy**

NIBS system will be marketed to medical centers, hospitals, geriatric facilities and pain clinics. Revenues are derived in two paths:

* System hardware and software sales.
* Disposable electrode grid for easy, fast, reproducible and hygienic operation of the acquired system.
* **Core Technology**

NIBS system provides a revolutionizing approach for determining brain network states of activity. By combining non-invasive brain monitoring and stimulation, NIBS system creates a 3D high spatiotemporal resolution image, reflecting dynamics of brain activity network states, which constitutes the key measurement for the identification of various brain disorders, essentially opening a window for an early stage, effective treatment.

* **Product Profile/Pipeline**

NIBS is currently conducting clinical trials in several hospitals in Israel. After establishing the system's proof of concept, current pipeline research is focused on chronic pain diagnosis and treatment, Alzheimer's disease diagnosis with its early precursor Mild Cognitive Impairment and focal Epilepsy. These trials will fully establish NIBS system strength in early stage diagnosis and differentiation of milder brain disorders.

* **What's Next?**
* As a part of our vision and business plan NIBS intends to :
* Further extend clinical trials to additional indications.
* Penetrate into target US and European markets via pivotal clinical studies.
* Establish strategic co-beneficial collaborations with pharmaceutical and medical device companies.